Revive Therapeutics Targets Cystinuria With Bucillamine

TORONTO - June 13, 2016 - PRLog -- Revive Therapeutics is expected to begin Phase 2 clinical trials with bucillamine in the next few months. Bucillamine is a drug that has been approved and used in Japan for over three decades, mostly for the treatment of rheumatoid arthritis. However, new data from Japan points to the potential use of bucillamine in treating a rare genetic disorder called cystinuria.

Cystinuria causes the formation of stones in the kidneys and bladder. The leading pharmaceutical product in the U.S. is called Thiola (tipronin), a mono-thiol compound that is effective in people who cannot tolerate penacillamine or are still having stone formations on alkali and water therapy.

Bucillamine is a dual-thiol compound and initial data out of Japan suggests the drug is more effective than Thiola, an estimated $250 million peak product in the U.S. Toronto-based Revive Therapeutics is developing bucillamine for cystinuria and other rare diseases. It's a move that could pay off substantially for shareholders of the tiny company.

In this report, BioNap analyst, Jason Napodano, looks at the potential for Revive's bucillamine and what is means for Revive Therapeutics >> http://www.bionapcfa.com/2016/06/revive-therapeutics-targ...